ERBB2 and breast carcinoma: In women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, pivotal clinical trials have demonstrated that CDK4/6 inhibitors, including ribociclib, palbociclib, and abemaciclib, significantly improve progression-free survival [11,12,13].